Clinical Trial Update: A 12-week Extension of the Phase III Study (D3820C00004) to Assess the Effect and Safety of NKTR-118 in Patients With Non-cancer-related Pain and Opioid-induced Constipation [Phase 3]

View source ↗

Summary

A 12-week extension of the Phase III study (D3820C00004) assessed the efficacy and safety of NKTR-118 for opioid-induced constipation in patients with non-cance…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Opioid-induced Constipation

Drugs mentioned

• NKTR-118

Snippet

Sponsor: AstraZeneca | Conditions: Opioid-Induced Constipation (OIC) | Phase 3 | Status: COMPLETED | Results posted: 2015-06-17